Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (5193)	12/20/2001 4:38:32 PM
From: scaram(o)uche	Respond to of 52153

Thanks V1 and Michael. Good luck to both camps (V1, enthusiastic, Michael waiting for a better entry). I think that I'll just watch. After all, they actually sell stuff.

To: Vector1 who wrote (5193)	12/21/2001 10:48:44 AM
From: Bob L	Read Replies (1) \| Respond to of 52153

Vector1, do you know what portion of the statin market consists of people with low HDL? Niacin and statin combo is usually recommended for high LDL and low HDL, but statin and bile resin combo is usually preferred for high LDL and adequate to high HDL.

To: Vector1 who wrote (5193)	12/22/2001 3:24:13 PM
From: Doc Bones	Respond to of 52153

Thus huge marketing dollars will be spent educating the market on the importance of the ratio of HDLs to LDLs and thereby increasing the overall size of the market. I think it would really help patients understand if they were told: "You want to be high in high-density and low in low-density (lipids)." "High-density is the 'good cholesterol'" is an arbitrary fact they have to remember in an area of confusing terminology, and easy to forget. This is especially true for the main customers, us geezers. Doc@saiditbeforebutwontshutup.com